[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Army Medical University, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":116},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,69,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100605815","rise-ileocecal-valve-functional-reconstruction-100605815",false,"NCT07167420","RISE Ileocecal Valve Functional Reconstruction","RISE Ileocecal Valve Functional Reconstruction for the Prevention of Postoperative Intestinal Dysfunction After Robotic\u002FLaparoscopic Right Hemicolectomy: a Single-blind, Two-arm, Multicenter Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* Subjects aged 18-80 years;\n* ASA score ≤ 3;\n* Patients newly diagnosed with tumors located in the appendix, ileocecal region, ascending colon, hepatic flexure of the colon, or the right one-third of the transverse colon, or those scheduled to undergo laparoscopic radical right hemicolectomy;\n* No history of other gastrointestinal diseases (except for intestinal polyps or gallstones);\n* Willing to participate in the study and sign the informed consent form;\n* Complete clinical data available.\n\nExclusion Criteria:\n\n* Presence of other malignant tumors in different organs;\n* Tumor invasion into adjacent organs;\n* Patients with concurrent infectious diseases or autoimmune diseases (e.g., Crohn's disease);\n* Patients with congenital or acquired metabolic disorders;\n* Use of antibiotics or other microbiota-altering medications within one month prior to enrollment;\n* Changes in surgical plan resulting in the resection not including the ileocecal valve.","ALL","18 Years","80 Years",{"count":20,"type":21},188,"ESTIMATED","INTERVENTIONAL",[24],"NA","The traditional surgical treatment for right-sided colon cancer involves the removal of an important structure, the ileocecal valve, which includes the ileocecal valve. This can lead to problems such as diarrhea and malnutrition in patients. This study reconstructs an artificial ileocecal valve through intraoperative suturing to compensate for the function of the original ileocecal valve. The control group will undergo the routine resection of the right-sided colon, including the ileocecal valve. This is a randomized controlled study. Patients enrolled will be randomly assigned to the experimental group (ileocecal valve reconstruction during surgery) or the control group (no ileocecal valve reconstruction), with no differences in other treatment procedures. After a series of follow-up observations, the research team will analyze the safety and effectiveness of the method of ileocecal valve reconstruction.",[27],"Right-sided Colon Cancer",[29,30,31],"right-sided colon cancer","laparoscopic surgery","ileocecal valve","NOT_YET_RECRUITING","2025-09-09",{"date":35,"type":36},"2025-09-11","ACTUAL",{"date":38,"type":21},"2025-10-01",{"date":40,"type":21},"2028-10-01",{"name":42,"class":43},"Army Medical University, China","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100592856","phase-4-a-prospective-cohort-study-on-primary-cutaneous-amyloidosis-100592856","NCT06998875","A Prospective Cohort Study on Primary Cutaneous Amyloidosis","A Prospective Cohort Study on the Efficacy and Safety Comparison of Tofacitinib Citrate Tablets Combined With Acitretin Capsules Versus Acitretin Capsules Alone in the Treatment of Primary Cutaneous Amyloidosis","Inclusion Criteria:\n\n* Age ≥ 18 years old, without infectious diseases such as \"hepatitis B\" and \"tuberculosis\" and major underlying diseases (gender not limited);\n\n  * \"Outpatient Diagnosis\" includes \"primary cutaneous amyloidosis\", \"macular amyloidosis\" or \"lichen amyloidosis\";\n\n    * Visited the outpatient department for PCA treatment for 4 times or more;\n\n      * The medication record shows \"Avastin Capsules\" and\u002For \"Tofacitinib Citrate\";\n\n        * The medical record fully records baseline characteristics, medication dosage, efficacy assessment and adverse events.\n\nExclusion Criteria:\n\n* Nodular amyloidosis or combined with other types of amyloidosis (such as systemic amyloidosis);\n\n  * During the study period, other immunosuppressants (such as glucocorticoids, methotrexate) or biologics were used;\n\n    * Incomplete medical records such as demographic data, laboratory parameters, prescription administration and patient prognosis, as well as irregular treatment, etc.",true,{"count":53,"type":21},56,[55],"PHASE4","The aim of this clinical trial is to find out whether the combination of tocilizumab tablets and acitretin capsules is more effective than acitretin capsules alone in treating primary cutaneous amyloidosis. It will also investigate the safety of the combination of tocilizumab tablets and acitretin capsules. The main questions it aims to answer are:\n\n1. Does the combination of tocilizumab tablets and acitretin capsules relieve the pruritus symptoms of the participants faster and reduce the pruritus score more than acitretin capsules alone?\n2. What medical problems will the participants encounter when taking tocilizumab tablets combined with acitretin capsules? The researchers compared the combination of tocilizumab tablets and acitretin capsules with acitretin capsules alone to see if the combination could better treat primary cutaneous amyloidosis without causing serious adverse reactions.\n\nParticipants will:\n\n1. Take the combination of tocilizumab tablets and acitretin capsules or acitretin capsules alone every day for 16 weeks.\n2. Visit the clinic once every 4 weeks for checkups and tests.\n3. Observe participants at 4 weeks, 12 weeks and 24 weeks after discontinuation of medication to determine the recurrence status.\n4. Collect the visual analogue scale (VAS) scores for pruritus, symptom severity (SCORAD) scores , rash area and severity, treatment response (EASI) scores, dermatological quality of life index (DLQI), and insomnia severity index (ISI) of participants before and after treatment.",[58],"Primary Cutaneous Amyloidosis","RECRUITING","2025-08-08",{"date":62,"type":36},"2025-08-13",{"date":64,"type":36},"2025-03-01",{"date":66,"type":21},"2025-12",{"name":42,"class":43},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100572790","the-comparison-of-single-catheter-and-double-catheter-adrenal-vein-sampling-methods-based-on-the-upper-limb-approach-100572790","NCT06737848","The Comparison of Single Catheter and Double Catheter Adrenal Vein Sampling Methods Based on the Upper Limb Approach","Inclusion Criteria:\n\n* Patients aged 18-70 years with hypertension.\n* Initial screening shows a standing aldosterone\u002Frenin ratio (ARR) \\> 3.7, a baseline aldosterone level \\> 10 ng\u002Fdl, aldosterone level \\> 6 ng\u002Fdl after a saline load test, or aldosterone decrease of less than 30% after a captopril suppression test, consistent with a diagnosis of primary aldosteronism.\n* Voluntary participation in the trial, with signed informed consent.\n\nExclusion Criteria:\n\n* Patients with an allergy to iodinated contrast agents.\n* Patients who are pregnant, breastfeeding, or planning to become pregnant.\n* Patients with severe comorbidities, such as renal failure, liver cirrhosis, metastatic tumors, or those who have had an acute stroke or acute myocardial infarction, as well as patients with a history of surgery within the past month.\n* Patients suspected of having adrenal cortical carcinoma.","70 Years",{"count":77,"type":21},70,[24],"Primary Aldosteronism (PA) is a clinical syndrome characterized by the autonomous overproduction of aldosterone by the adrenal cortex's zona glomerulosa, leading to hypertension, elevated aldosterone levels, and suppressed renin activity as the primary manifestations. Studies have shown that the prevalence of PA in an unselected hypertensive population ranges from 5% to 11% , while the prevalence in patients with resistant hypertension is approximately 20% . PA is one of the most common causes of secondary hypertension , and its prevalence increases with rising blood pressure levels. Due to the adverse effects of PA on the heart, arterial walls, and kidneys, it contributes to the occurrence of cardiovascular events, with atrial fibrillation being the most common . In summary, PA is characterized by rapid onset, significant symptoms, obscurity, and severe complications, making early diagnosis and targeted treatment essential for prevention.\n\nThis study aims to explore a quasi-selected prospective randomized controlled method to compare the clinical efficacy differences between single-catheter and dual-catheter adrenal sampling via the right upper limb approach. The study seeks to clarify the effectiveness and safety of single-catheter sampling from the upper limb, providing a more efficient and cost-effective solution for the subtype diagnosis of patients with Primary Aldosteronism (PA).",[81],"Primary Aldosteronism","2024-12-12",{"date":84,"type":36},"2024-12-17",{"date":86,"type":21},"2024-12-30",{"date":88,"type":21},"2025-07-31",{"name":42,"class":43},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":68},"100550332","photodynamic-therapy-with-hydrogel-dressing-for-chronic-wounds-100550332","NCT06445699","Photodynamic Therapy With Hydrogel Dressing for Chronic Wounds","Investigation the Clinical Effectiveness of Combination Topical Aminolaevulinic Acid-Photodynamic Therapy With Hydrogel Dressing for Treatment Chronic Cutaneous Wounds","Inclusion Criteria:\n\n* 1\\) patients with chronic wounds caused by trauma or surgery who failed to heal after traditional formal medical treatment at least over three months;\n* 2\\) Patients with stable vital signs who had no systemic medical disease and did not take glucocorticoids, immunosuppressive agents, or anticoagulants during the entire treatment process;\n* 3\\) Participants provided signed informed consent, were able to comply with the program, were willing to participate in follow-up, and were able to cooperate in the observation of adverse events and efficacy;\n* 4\\) The diameter of the skin wound should not exceed 10 centimeters.\n\nExclusion Criteria:\n\n* 1\\) Patients are allergic to ALA;\n* 2\\) Women with recent fertility, pregnancy or lactation plans;\n* 3\\) Patients with deepening wounds or worsening infections;\n* 4\\) Poor compliance leading to an inability to complete the treatment in its entirety;\n* 5\\) Cutaneous ulcer caused by vascular disease, autoimmune diseases, metabolic diseases, local or metastatic malignant tumors.",{"count":98,"type":21},69,[24],"63 patients with chronic infectious wounds were enrolled in the controlled study. They were randomly divided into three groups equally. Group 1 (Grp.1): The patients received hydrogel dressing change at three days intervals. Group 2 (Grp.2): The patients received ALA-PDT treatment at ten days intervals for 4 sessions. Groups 3 (Grp.3): The patients received ALA-PDT at ten days intervals for 4 sessions combined with hydrogel dressing change every three days intervals. The wound healing rate, total effective rate, patient satisfaction, adverse reaction, and recurrence were assessed in all groups.",[102],"Photodynamic Therapy",[104,105,106,107],"Wound healing","Aminolaevulinic acid","Photodynamic therapy","Hydrogel dressing","2024-07-29",{"date":110,"type":36},"2024-07-30",{"date":112,"type":36},"2023-01-01",{"date":114,"type":21},"2024-08",{"name":42,"class":43},""]